IL-17, IL-23, and p73 expression in cutaneous melanoma

Ganzetti, Giulia; Rubini, Corrado; Campanati, Anna; Zizzi, Antonio; Molinelli, Elisa; Rosa, Laura; Simonacci, Francesco; Offidani, Annamaria

doi:10.1097/cmr.0000000000000151

Cited by 25 publications

(15 citation statements)

References 19 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They studied the expression of interleukin‐17 (IL‐17), IL‐23, and p73 in 35 malignant melanomas comparing them with benign melanocytic nevi and Spitz nevi. Their results showed a greater IL‐17 and IL‐23 immunohistochemistry expression in the melanoma group than in ordinary benign nevi . These results could suggest a possible IL‐17, IL‐23, and p73 involvement in cutaneous melanomas with a hypothetical impact on melanoma invasiveness.…”

Section: Il‐17 and Oncological Skin Diseasesmentioning

confidence: 88%

IL‐17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art

et al. 2019

View full text Add to dashboard Cite

Recent data support the theory of the involvement of IL‐17 in the pathogenesis of several chronic inflammatory skin diseases (psoriasis, atopic dermatitis, acne, hidradenitis suppurativa) and autoimmune skin diseases (alopecia areata, vitiligo, bullous diseases). Even if the role of IL‐17 in inflammatory and autoimmune diseases has been reported extensively, its role in tumor is still controversial. Some reports show that Th17 cells eradicate tumors, while others reveal that they promote the initiation and early growth of tumors. Herein, we review the role of IL‐17 in the involvement of some common dermatologic diseases: psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, vitiligo, melanoma, and nonmelanoma skin cancers.

show abstract

Section: Il‐17 and Oncological Skin Diseasesmentioning

confidence: 88%

IL‐17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Additionally, IL-17/IL-17RA pathway stimulated cell proliferation of mouse B16F10 and human A375 and A2058 cell lines ( Chen et al, 2019 ). IL-17 and IL-23 immunohistochemistry expression were increased in the melanoma tissues, possibly enhancing VEGF expression and angiogenesis ( Ganzetti et al, 2015 ). Therefore, these analyses supported the hypothesis of the importance of hypoxia microenvironment in the regulation of the biological behavior of tumor cells and surrounding non-tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Identification of Signatures of Prognosis Prediction for Melanoma Using a Hypoxia Score

Shou

Yang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Melanoma is one of the most aggressive cancers. Hypoxic microenvironment affects multiple cellular pathways and contributes to tumor progression. The purpose of the research was to investigate the association between hypoxia and melanoma, and identify the prognostic value of hypoxia-related genes. Based on the GSVA algorithm, gene expression profile collected from The Cancer Genome Atlas (TCGA) was used for calculating the hypoxia score. The Kaplan–Meier plot suggested that a high hypoxia score was correlated with the inferior survival of melanoma patients. Using differential gene expression analysis and WGCNA, a total of 337 overlapping genes associated with hypoxia were determined. Protein-protein interaction network and functional enrichment analysis were conducted, and Lasso Cox regression was performed to establish the prognostic gene signature. Lasso regression showed that seven genes displayed the best features. A novel seven-gene signature (including ABCA12, PTK6, FERMT1, GSDMC, KRT2, CSTA, and SPRR2F) was constructed for prognosis prediction. The ROC curve inferred good performance in both the TCGA cohort and validation cohorts. Therefore, our study determined the prognostic implication of the hypoxia score in melanoma and showed a novel seven-gene signature to predict prognosis, which may provide insights into the prognosis evaluation and clinical decision making.

show abstract

“…Similarly, Liu et al [8] also reported that TP73 was overexpressed in cervical cancer tissues compared with normal cervical tissues. In addition, high expression of TP73 was suggested in several kinds of human tumors such as breast cancer [15,16], esophageal cancer [17], thymic carcinoma [18], extrahepatic bile duct carcinoma [19], cholangiocellular carcinoma [20], hepatocellular carcinoma [21,22], gastric cancer [23,24], colorectal cancer [25–27], ovarian cancer [28], laryngeal cancer [29], parotid gland carcinoma [30], cutaneous melanoma [31] and retinoblastoma [32]. However, low TP73 expression was observed in bladder cancer and head and neck squamous cell carcinoma, compared to corresponding normal tissues [33,34].…”

Section: Discussionmentioning

confidence: 99%

TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients

Guo²

2019

Bioscience Reports

View full text Add to dashboard Cite

Tumor protein p73 (TP73) has been reported to be dysregulated in various types of human cancer and associated with clinical progression and outcome. Owing to the lack of reports on the correlation between TP73 protein expression and clinicopathologic features of cervical cancer, the aim of our research was to explore the clinical and prognostic significance of TP73 protein expression in cervical cancer patients. In our study, TP73 protein expression was detected by immunochemistry in 118 paraffin-embedded cervical cancer tissue specimens and 40 paraffin-embedded normal cervical epithelium tissue specimens. In the results, we found cervical cancer tissues exhibited high TP73 expression in comparison with normal cervical epithelium tissues, which was consistent with the expression status of TP73 in The Cancer Genome Atlas (TCGA) database. Furthermore, we analyzed the relationships between TP73 expression and clinicopathologic features through using the chi-square test or Fisher’s exact test, and found high expression of TP73 was markedly associated with early clinical stage, less lymph node metastasis, absent distant metastasis, squamous cell carcinoma and favorable histological grade. The Kaplan–Meier method and log-rank test were performed based on the expression level of TP73 in a cervical cancer cohort from the TCGA database, and showed that TP73 expression was positively correlated with overall survival time in cervical cancer patients. Moreover, univariate and multivariate Cox proportional hazards regression model indicated that high TP73 expression was identified as an independent factor for predicting favorable overall survival in cervical cancer patients. In conclusion, TP73 expression is increased in cervical cancer tissues and cells, and acts as a credible biomarker for predicting favorable overall survival in cervical cancer patients.

show abstract

IL-17, IL-23, and p73 expression in cutaneous melanoma

Cited by 25 publications

References 19 publications

IL‐17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art

IL‐17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art

Identification of Signatures of Prognosis Prediction for Melanoma Using a Hypoxia Score

TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients

Contact Info

Product

Resources

About